Yakup Ergün, Medical Oncologist at Bower Hospital, shared an by John D. Groarke et al. published in NEJM, on X:
“Ponsegromab for the Treatment of Cancer Cachexia.
The placebo-controlled phase 2 study presented at ESMO 2024 showed that Ponsegromab, a monoclonal antibody developed against GDF-15, increases weight gain and reduces cachexia symptoms.”
Ponsegromab for the Treatment of Cancer Cachexia | NEJM
Authors: John D. Groarke et al.
